News | Heart Valve Technology | December 31, 2016

First U.S. Transcatheter Tricuspid NaviGate Valve Successfully Implanted

NaviGate, GATE tricuspid Atrioventricular Valved Stent AVS, transcatheter tricuspid valve replacement

December 31, 2016 — NaviGate Cardiac Structures Inc. (NCSI) announced that a novel valved stent that can capture the enlarged annulus in patients suffering from functional tricuspid regurgitation (FTR) was implanted in a patient presenting with massive incompetence of the tricuspid valve.

The patient, a 64-year-old female with an extensive history of severe tricuspid regurgitation (TR 4+) that invariably results in right heart failure (RHF), a lethal condition, was successfully treated with the GATE tricuspid Atrioventricular Valved Stent (AVS) from NCSI. The cardiac team from the Cleveland Clinic implanted the AVS with catheter-guided technique under a compassionate plea from the patient. A compassionate plea allows a special permission for medical procedures deemed to be the last resort for patients with conditions for which no approved device or medicine exists.

After the implantation, the valve demonstrated excellent valvular function, indicating correction of the massive regurgitation problem. The patient became stable and was closely observed by the cardiac team and at 30 days post implantation is doing quite well.

“This is a step forward in the treatment of tricuspid regurgitation. The hope is to provide a device that is able to capture the diseased tricuspid valve annulus, which has been enlarged inordinately by the ravages of functional tricuspid regurgitation, thus causing a reverse flow of venous blood from the right heart that should go to the lungs,” said Cleveland Clinic cardiovascular surgeon Jose L. Navia, M.D., a member of NaviGate’s scientific advisory board and company shareholder.

“This patient’s annulus measured 49.7 millimeters in diameter, and there are currently no valved stents that can secure such a dimension without extending into any of the chambers and still provide valvular function, yet there are millions of patients in the USA and worldwide presenting with this problem,” said Samir Kapadia, M.D., Cleveland Clinic interventional cardiologist.  Kapadia also serves as a scientific advisory board member to NaviGate.

The GATE tricuspid AVS has been developed and manufactured by NCSI, which licensed the seminal technology from Cleveland Clinic. The technology platform, initially explored at Cleveland Clinic, includes percutaneous valve devices for mitral valve replacement and tissue-preservation techniques that remove the toxic tissue fixatives, which — although allowing the fabrication of biological valve replacement from animal tissues leaves residuals that are thought to promote untoward effects for the longevity of tissue. The technology removes most of the water so that the device can be shipped in the “dry form.”

NCSI made modifications to the device that differentiates it from all others presently manufactured for atrioventricular valves. The unique design of this device in the form of a diffuser or truncated cone exhibits a low-height profile that can be more easily threaded through the vasculature to reach the atrioventricular valves, allowing it to reside without protrusion into either of the adjacent chambers (atrium or ventricle) for mitral or tricuspid valves.

“Our quest is to fully develop and provide the medical community with systems of devices to replace the lost function of both atrioventricular valves of the heart, the tricuspid and the mitral, and to develop the easiest, most user-friendly and most secure methods for their use," said R. C. Quijano, president and CEO of NCSI. "Not an easy task, granted. These devices could be used by cardiologists delivered either by threading through the vasculature (so long as the patient has no blood clots in those vessels), or alternatively through minimally invasive surgical and beating-heart techniques by the surgeon when the former is not advisable.”

NCSI is presently conducting clinical trials (Chile and Poland) of its NAVI mitral valved stent for correction of functional mitral regurgitation (FMR), a similar deadly condition affecting millions of patients worldwide. One patient in Chile has just passed the one-year mark and returned to work with a functional valve.

The healthcare market for these two conditions reaches close to $20 billion yearly, which explains the extensive effort being made by many large multinational medical companies as well as the plurality of start-up venture companies that have focused for the last decade on mitral replacement and repair and those that are now pursuing the repair and replacement of the “forgotten” tricuspid valve.

Read the article "NaviGate Reports First Patient Treated With its Trancatheter Mitral Valve."

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," and discussion with Rebecca Hahn, M.D.

For more information: www.navigatecsi.com

Related Content

SpectraWave is developing a a new intravascular imaging system that combines two currently available modalities. This likely includes optical coherence tomography (OCT), left, which can define structures within the vessel and vessel wall.  Near infrared spectroscopy (NIRS), right, enables a spectral chemical analysis of the vessel walls to show areas of high lipid content, and specifically can identify lipid-core plaques that are associated with heart attack-causing plaque ruptures.

News | Cath Lab | February 16, 2021
February 16, 2021 – SpectraWave Inc.
Videos | Cath Lab | February 04, 2021
Cindy Grines, M.D., MSCAI, FACC, president
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over